Recent Updates
Recently added Catalysts
ANTX Positive Sentiment

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AN2 Therapeutics will present at the Jefferies Global Healthcare Conference in London on November 16, 2026. CEO Eric Easom will lead the presentation, and management will hold one-on-one meetings. This event highlights the company's ongoing commitment to sharing its developments in novel therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Eric Easom will present at a major global healthcare conference.
  • Management team will hold one-on-one meetings with investors.
  • Company announced a webcast for broader investor access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
2.3%
average across 5 past catalysts
Cash runway
~31 mo
Low dilution risk
Lead asset
Epetraborole
Phase 2 · Polycythemia Vera (SNOMED CT: 109992005)

Full Press Release Details

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 9:30 am GMT and members of management will be available for 1x1 meetings.A webcast of the presentation can be accessed

Frequently Asked Questions

When will AN2 Therapeutics present at the conference?

AN2 Therapeutics will present on November 16, 2026.

Who will lead the presentation for AN2 Therapeutics?

The presentation will be led by CEO Eric Easom.

Where is the Jefferies Global Healthcare Conference held?

The conference will take place in London.

Will there be opportunities for meetings with management?

Yes, management will be available for one-on-one meetings.

ShareAdd on Google
Tags: ANTX AN2 Therapeutics Jefferies Conference Eric Easom biopharmaceuticals clinical stage
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$80M liquidity · $2M/mo burn
~31 mo
Low dilution risk
Lead asset
EpetraborolePhase 2
Polycythemia Vera (SNOMED CT: 109992005) →

Catalyst track record

+34%
best trade around ANTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ANTX.

See every catalyst's timing & PoA →